

AMENDMENT

In the Claims

The following Listing of Claims, in which deleted text appears as ~~struck-through~~ and inserted text appears underlined, will replace all prior listings, and versions, of claims in the application.

Listing of Claims

Claims 1-54 (cancelled)

55. (New): An isolated recombinant polypeptide comprising:

- (a) the amino acid sequence SEQ ID NO:2 or
- (b) an immunogenic fragment of at least 40 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a composition which can include an adjuvant, or conjugated to a suitable carrier, induces an antibody or T-cell immune response that recognizes the polypeptide SEQ ID NO:2.

56. (New) The isolated recombinant polypeptide of claim 55, wherein the polypeptide comprises the amino sequence SEQ ID NO:2.

57. (New) The isolated recombinant polypeptide of claim 55, wherein the polypeptide consists of the amino sequence SEQ ID NO:2.

58. (New) The isolated recombinant polypeptide of claim 55, wherein the polypeptide comprises an immunogenic fragment of at least 40 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a composition which can include an adjuvant, or conjugated to a suitable carrier, induces an antibody or T-cell immune response that recognizes the polypeptide SEQ ID NO:2.

59. (New) An isolated recombinant fusion protein comprising the polypeptide of claim 55.

60. (New) An isolated recombinant fusion protein comprising the polypeptide of claim 56.

61. (New) An isolated recombinant fusion protein comprising the polypeptide of claim 58.

62. (New) An immunogenic composition comprising the recombinant polypeptide of claim 55 [and a pharmaceutically acceptable carrier].

63. (New) An immunogenic composition comprising the isolated recombinant fusion protein of claim 59 [and a pharmaceutically acceptable carrier].

64. (New) A vaccine comprising the polypeptide of claim 55 and a pharmaceutically acceptable carrier.

65. (New) A vaccine comprising the polypeptide of claim 56 and a pharmaceutically acceptable carrier.

66. (New) A vaccine comprising the polypeptide of claim 58 and a pharmaceutically acceptable carrier.

67. (New) The vaccine according to Claim 64, 65, or 66, further comprising at least one other *Moraxella catarrhalis* antigen.

68. (New) A method for inducing an immune response in a mammal comprising administration of the isolated recombinant polypeptide of claim 55.